Kim EY - Search Results

1

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators. Bergmeijer TO, et al. Among authors: kim ey, kim hs. Am Heart J. 2018 Apr;198:152-159. doi: 10.1016/j.ahj.2017.12.010. Epub 2017 Dec 17. Am Heart J. 2018. PMID: 29653637 Free PMC article. Review.

2

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG. Kim HS, et al. Among authors: kim ey. Pharmacogenet Genomics. 2009 Feb;19(2):103-12. doi: 10.1097/FPC.0b013e32831a9ae3. Pharmacogenet Genomics. 2009. PMID: 19077919

3

Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals.

Jiang F, Yeo CW, Lee SS, Oh MK, Ghim JL, Shon JH, Kim HS, Kim EY, Kim DH, Shin JG. Jiang F, et al. Among authors: kim ey, kim dh, kim hs. Pharmacogenet Genomics. 2013 Mar;23(3):175-9. doi: 10.1097/FPC.0b013e32835de25e. Pharmacogenet Genomics. 2013. PMID: 23292115

4

The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.

Kim HS, Kim GY, Yeo CW, Oh M, Ghim JL, Shon JH, Kim EY, Kim DH, Shin JG. Kim HS, et al. Among authors: kim gy, kim ey, kim dh. Br J Clin Pharmacol. 2014 May;77(5):821-30. doi: 10.1111/bcp.12236. Br J Clin Pharmacol. 2014. PMID: 24001154 Free PMC article. Clinical Trial.

5

CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.

Kim HS, Chang K, Koh YS, Park MW, Choi YS, Park CS, Oh M, Kim EY, Shon JH, Shin JG, Seung KB. Kim HS, et al. Among authors: kim ey. Circ Cardiovasc Genet. 2013 Oct;6(5):514-21. doi: 10.1161/CIRCGENETICS.113.000109. Epub 2013 Sep 9. Circ Cardiovasc Genet. 2013. PMID: 24019397 Clinical Trial.

6

The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.

Kim HS, Cho DY, Park BM, Bae SK, Yoon YJ, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG. Kim HS, et al. Among authors: kim ey, kim dh. J Clin Pharmacol. 2014 Aug;54(8):850-7. doi: 10.1002/jcph.225. Epub 2013 Nov 26. J Clin Pharmacol. 2014. PMID: 24214141 Clinical Trial.

7

Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.

Jeong HE, Lee SJ, Cha EY, Kim EY, Kim HS, Song YH, Shin JG. Jeong HE, et al. Among authors: kim ey, kim hs. Int J Mol Sci. 2014 May 5;15(5):7699-710. doi: 10.3390/ijms15057699. Int J Mol Sci. 2014. PMID: 24857912 Free PMC article.

8

Prioritizing Approaches to Engage Community Members and Build Trust in Biobanks: A Survey of Attitudes and Opinions of Adults within Outpatient Practices at the University of Maryland.

Overby CL, Maloney KA, Alestock TD, Chavez J, Berman D, Sharaf RM, Fitzgerald T, Kim EY, Palmer K, Shuldiner AR, Mitchell BD. Overby CL, et al. Among authors: kim ey. J Pers Med. 2015 Jul 28;5(3):264-79. doi: 10.3390/jpm5030264. J Pers Med. 2015. PMID: 26226006 Free PMC article.

9

The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.

Kim HS, Lim Y, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG. Kim HS, et al. Among authors: kim ey, kim dh. Br J Clin Pharmacol. 2016 Feb;81(2):301-12. doi: 10.1111/bcp.12794. Epub 2015 Dec 28. Br J Clin Pharmacol. 2016. PMID: 26426352 Free PMC article. Clinical Trial.

10

Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.

Kim DJ, Kim HS, Oh M, Kim EY, Shin JG. Kim DJ, et al. Among authors: kim ey, kim hs. Appl Health Econ Health Policy. 2017 Oct;15(5):657-667. doi: 10.1007/s40258-017-0317-y. Appl Health Econ Health Policy. 2017. PMID: 28247199

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,023 results

Search Page